<DOC>
	<DOC>NCT01013259</DOC>
	<brief_summary>Due to the worldwide increasing prevalence of the allergic rhinoconjunctivitis, new therapeutical strategies are needed. The symptomatic treatment with topical and systemic antihistamines and corticosteroids are often insufficient. E.coli Nissle 1917 has immunomodulatory capacities and reveals less side effects. E.coli Nissle 1917 has no sedative properties and exhibits no hepatotoxic qualities. Thus, E.coli Nissle 1917 represents a new relevant therapeutical agent.</brief_summary>
	<brief_title>Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>clinical relevant grass pollen allergy with required treatment since 2 years positive skin prick test to grass positive sIgE towards grass (CAP 2) written informed consent perennial rhinoconjunctivitis sinusitis chronic diarrhoea and other existing severe gastrointestinal diseases current specific immunotherapy to grass pollen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>E.coli</keyword>
	<keyword>Mutaflor</keyword>
	<keyword>grass pollen</keyword>
	<keyword>rhinoconjunctivitis</keyword>
	<keyword>rhinoconjunctivitis caused by grass pollen</keyword>
</DOC>